上咽頭がん治療の世界市場レポート 2025年

上咽頭がん治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には16億9,000万米ドルに成長し、CAGRは6.9%となります。予測期間の成長は、新たな標的治療、個別化医療アプローチ、治療アクセスの世界的拡大、臨床試験の成功、早期発見への継続的な注力に起因しています。予測期間の主な動向としては、併用療法の導入、支持療法とQOLの重視、治療計画における人工知能（AI）の統合、臨床試験と研究イニシアチブの拡大、早期発見のための画像技術の強化などが挙げられます。

上咽頭がん治療市場は、タバコ消費量の増加により成長が見込まれます。タバコはタバコの葉を乾燥させたもので、一般に喫煙や咀嚼に使用され、さまざまなタバコ製品の主要成分となっています。タバコの使用が増えると上咽頭がんを発症するリスクが高まり、手術、放射線療法、化学療法、標的療法などの効果的な治療オプションが必要となります。注目すべきは、カナダ統計局の報告によると、2023年7月のカナダにおけるタバコの生産量は6月と比較して2.2％急増し、タバコの販売量も2.6％増加し、6月には14億本に達したことです。したがって、タバコ消費量の増加が上咽頭がん治療市場の拡大を牽引しています。

上咽頭がん治療市場は、エプスタイン・バー・ウイルス（EBV）感染の急増により成長すると予測されます。EBVはヘルペスウイルス科に属する感染力の強い感染症で、上咽頭がん（NPC）と密接な関係があります。このウイルスは主に体液、特に唾液を介して広がり、NPCの開発と強く関連しています。米国国立医学図書館は、2023年8月に世界の成人人口の95％がEBVに暴露されていると報告しています。さらに米国では、小児および青少年におけるEBVの有病率は様々であり、特定の年齢層における感染率は約54％、18～19歳の青少年では約82.9％とピークに達しています。その結果、EBV感染率の上昇が上咽頭がん治療市場の成長を牽引しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、コロナ、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界上咽頭がん治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の上咽頭がん治療市場：成長率分析
• 世界の上咽頭がん治療市場の実績：規模と成長, 2019-2024
• 世界の上咽頭がん治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界上咽頭がん治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の上咽頭がん治療市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非角化性未分化がん
• 非角化性分化がん
• 角化扁平上皮がん
• 世界の上咽頭がん治療市場薬物による、実績と予測, 2019-2024, 2024-2029F, 2034F
• エレンス
• タキソテール
• ブレオマイシン
• メトトレキサート
• 世界の上咽頭がん治療市場セラピーによって、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 免疫療法
• 放射線治療
• その他の治療法
• 世界の上咽頭がん治療市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界の上咽頭がん治療市場、非角化性未分化がんのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 低分化型
• よく分化したタイプ
• 世界の上咽頭がん治療市場非角化性分化がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 差別化タイプ
• 世界の上咽頭がん治療市場角化扁平上皮がんの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 角質化タイプ

第7章 地域別・国別分析

• 世界の上咽頭がん治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の上咽頭がん治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 上咽頭がん治療市場：競合情勢
• 上咽頭がん治療市場：企業プロファイル
  • Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• AstraZeneca plc
• Eli Lilly and Company
• Amgen Inc.
• C.H. Boehringer Sohn AG & Co. KG.
• Regeneron Pharmaceuticals Inc.
• Astellas Pharma Inc.
• Eisai Co. Ltd.
• Incyte Corporation
• Ipsen S.A.
• Dr. Reddys Laboratories Ltd.
• Hikma Pharmaceuticals plc
• Exelixis Inc.
• BeiGene Ltd
• Taiho Pharmaceutical Co. Ltd.
• Simcere Pharmaceutical Group

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 上咽頭がん治療市場2029：新たな機会を提供する国
• 上咽頭がん治療市場2029：新たな機会を提供するセグメント
• 上咽頭がん治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Nasopharyngeal carcinoma (NPC) is a type of cancer that originates in the nasopharynx, the upper part of the throat located behind the nose. The treatment of nasopharyngeal carcinoma involves various medical interventions and therapies aimed at managing and combating cancerous growth in the nasopharynx, with goals such as achieving remission, managing symptoms, and improving the overall well-being of the patient.

The main types of nasopharyngeal carcinoma include non-keratinizing undifferentiated carcinoma, non-keratinizing differentiated carcinoma, and keratinizing squamous cell carcinoma. Non-keratinizing undifferentiated carcinoma is characterized by the absence of keratin, a protein typically found in the outer layers of the skin. Treatment for this type of carcinoma typically involves a combination of radiation therapy and chemotherapy. Chemotherapy drugs such as ellence, taxotere, bleomycin, and methotrexate are employed in various treatment modalities, including chemotherapy, immunotherapy, radiation therapy, and others. These drugs are distributed through hospital pharmacies, retail pharmacies, and online pharmacy channels.

The nasopharyngeal carcinoma treatment market research report is one of a series of new reports from The Business Research Company that provides nasopharyngeal carcinoma treatment market statistics, including nasopharyngeal carcinoma treatment industry global market size, regional shares, competitors with a nasopharyngeal carcinoma treatment market share, detailed nasopharyngeal carcinoma treatment market segments, market trends and opportunities, and any further data you may need to thrive in the nasopharyngeal carcinoma treatment industry. This nasopharyngeal carcinoma treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The nasopharyngeal carcinoma treatment market size has grown strongly in recent years. It will grow from $1.21 billion in 2024 to $1.29 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth in the historic period can be attributed to high prevalence in endemic regions, advancements in radiation therapy, improved diagnostic methods, awareness and screening programs, collaborative research initiatives.

The nasopharyngeal carcinoma treatment market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to emerging targeted therapies, personalized medicine approaches, global expansion of treatment access, clinical trial successes, continued focus on early detection. Major trends in the forecast period include implementation of combination therapies, focus on supportive care and quality of life, integration of artificial intelligence (ai) in treatment planning, expansion of clinical trials and research initiatives, enhanced imaging technologies for early detection.

The nasopharyngeal carcinoma treatment market is expected to witness growth propelled by the rise in tobacco consumption. Tobacco, derived from dried leaves of the tobacco plant, is commonly used for smoking or chewing and is a key component in various tobacco products. Increased tobacco use elevates the risk of developing nasopharyngeal carcinoma, necessitating effective treatment options such as surgery, radiation therapy, chemotherapy, and targeted therapies. Notably, Statistics Canada reported a 2.2% surge in cigarette production in Canada in July 2023 compared to June, coupled with a 2.6% increase in cigarette sales, reaching 1.4 billion units in June. Hence, the escalating tobacco consumption drives the expansion of the nasopharyngeal carcinoma treatment market.

The nasopharyngeal carcinoma treatment market is projected to grow due to an upsurge in Epstein-Barr virus (EBV) infections. EBV, a highly contagious infection belonging to the herpesvirus family, is closely linked to Nasopharyngeal Carcinoma (NPC). The virus spreads primarily through bodily fluids, notably saliva, and is strongly associated with NPC development. The National Library of Medicine reported a staggering 95% global adult population exposure to EBV in August 2023. Moreover, in the United States, EBV prevalence among children and adolescents varies, with infection rates around 54% in certain age groups and peaking at approximately 82.9% among adolescents aged 18 to 19. Consequently, the escalating incidence of EBV infections drives growth in the nasopharyngeal carcinoma treatment market.

Major players in the nasopharyngeal carcinoma treatment market are concentrating on developing advanced technological solutions, such as Loqtorzi, to meet various critical industry needs. Loqtorzi is an oral medication for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that targets tumor growth while minimizing side effects. It can be utilized alongside other therapies to boost effectiveness. For example, in January 2024, Coherus BioSciences, a US-based biopharmaceutical firm, launched LOQTORZI (toripalimab-tpzi), the first FDA-approved treatment for nasopharyngeal carcinoma (NPC) applicable across all lines of therapy. This anti-PD-1 monoclonal antibody is indicated for use in conjunction with chemotherapy for first-line treatment and as a standalone therapy for patients who have progressed after platinum-based chemotherapy. Clinical trials have demonstrated that LOQTORZI significantly enhances progression-free survival and overall survival. The drug is currently available through select specialty distributors, and Coherus is committed to improving patient access and education through initiatives like NPCFacts.com, marking a notable advancement in treatment options for this aggressive cancer type.

In April 2024, Genmab A/S, a biotechnology company based in Denmark, acquired ProfoundBio Inc. for $1.8 billion. This acquisition aims to significantly enhance Genmab's oncology portfolio by providing access to next-generation antibody-drug conjugates (ADCs) and proprietary technology platforms. ProfoundBio Inc. is a US-based clinical-stage biotechnology firm that develops antibody-based therapeutics for cancer patients.

Major companies operating in the nasopharyngeal carcinoma treatment market report are Sanofi S.A., Pfizer Inc., Merck & Co. Inc., Novartis AG, Bristol Myers Squibb Company, AstraZeneca PLC, Eli Lilly and Company, Amgen Inc., C.H. Boehringer Sohn AG & Co. KG., Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Eisai Co. Ltd., Incyte Corporation, Ipsen S.A., Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals PLC, Exelixis Inc., BeiGene Ltd., Taiho Pharmaceutical Co. Ltd., Simcere Pharmaceutical Group, Daiichi Sankyo Company Limited, BioDiem Ltd., Coherus BioSciences Inc., Shanghai Junshi Bioscience Co Ltd., Genentech Inc., Helsinn Group, Cyclacel Pharmaceuticals Inc., Advenchen Laboratories LLC.

North America was the largest region in the nasopharyngeal carcinoma treatment market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the nasopharyngeal carcinoma treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the nasopharyngeal carcinoma treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The nasopharyngeal carcinoma treatment market consists of revenues earned by entities by providing proton therapy, brachytherapy, external-beam radiation therapy services. The market value includes the value of related goods sold by the service provider or included within the service offering. The nasopharyngeal carcinoma treatment market also includes sales of loqtorzi, cetuximab, gemcitabine, and cisplatin used in nasopharyngeal carcinoma treatment. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Nasopharyngeal Carcinoma Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on nasopharyngeal carcinoma treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for nasopharyngeal carcinoma treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The nasopharyngeal carcinoma treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Types: Non-Keratinizing Undifferentiated Carcinoma; Non-Keratinizing Differentiated Carcinoma; Keratinizing Squamous Cell Carcinoma
• 2) By Drug: Ellence; Taxotere; Bleomycin; Methotrexate
• 3) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Other Therapies
• 4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• Subsegments:
• 1) By Non-Keratinizing Undifferentiated Carcinoma: Poorly Differentiated Type; Well-Differentiated Type
• 2) By Non-Keratinizing Differentiated Carcinoma: Differentiated Type
• 3) By Keratinizing Squamous Cell Carcinoma: Keratinizing Type
• Companies Mentioned: Sanofi S.A.; Pfizer Inc.; Merck & Co. Inc.; Novartis AG; Bristol Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Nasopharyngeal Carcinoma Treatment Market Characteristics

3. Nasopharyngeal Carcinoma Treatment Market Trends And Strategies

4. Nasopharyngeal Carcinoma Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Nasopharyngeal Carcinoma Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Nasopharyngeal Carcinoma Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Nasopharyngeal Carcinoma Treatment Market Growth Rate Analysis
• 5.4. Global Nasopharyngeal Carcinoma Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Nasopharyngeal Carcinoma Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Nasopharyngeal Carcinoma Treatment Total Addressable Market (TAM)

6. Nasopharyngeal Carcinoma Treatment Market Segmentation

• 6.1. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Non-Keratinizing Undifferentiated Carcinoma
• Non-Keratinizing Differentiated Carcinoma
• Keratinizing Squamous Cell Carcinoma
• 6.2. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ellence
• Taxotere
• Bleomycin
• Methotrexate
• 6.3. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Radiation Therapy
• Other Therapies
• 6.4. Global Nasopharyngeal Carcinoma Treatment Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.5. Global Nasopharyngeal Carcinoma Treatment Market, Sub-Segmentation Of Non-Keratinizing Undifferentiated Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Poorly Differentiated Type
• Well-Differentiated Type
• 6.6. Global Nasopharyngeal Carcinoma Treatment Market, Sub-Segmentation Of Non-Keratinizing Differentiated Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Differentiated Type
• 6.7. Global Nasopharyngeal Carcinoma Treatment Market, Sub-Segmentation Of Keratinizing Squamous Cell Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Keratinizing Type

7. Nasopharyngeal Carcinoma Treatment Market Regional And Country Analysis

• 7.1. Global Nasopharyngeal Carcinoma Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Nasopharyngeal Carcinoma Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market

• 8.1. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Nasopharyngeal Carcinoma Treatment Market

• 9.1. China Nasopharyngeal Carcinoma Treatment Market Overview
• 9.2. China Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Nasopharyngeal Carcinoma Treatment Market

• 10.1. India Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Nasopharyngeal Carcinoma Treatment Market

• 11.1. Japan Nasopharyngeal Carcinoma Treatment Market Overview
• 11.2. Japan Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Nasopharyngeal Carcinoma Treatment Market

• 12.1. Australia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Nasopharyngeal Carcinoma Treatment Market

• 13.1. Indonesia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Nasopharyngeal Carcinoma Treatment Market

• 14.1. South Korea Nasopharyngeal Carcinoma Treatment Market Overview
• 14.2. South Korea Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Nasopharyngeal Carcinoma Treatment Market

• 15.1. Western Europe Nasopharyngeal Carcinoma Treatment Market Overview
• 15.2. Western Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Nasopharyngeal Carcinoma Treatment Market

• 16.1. UK Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Nasopharyngeal Carcinoma Treatment Market

• 17.1. Germany Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Nasopharyngeal Carcinoma Treatment Market

• 18.1. France Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Nasopharyngeal Carcinoma Treatment Market

• 19.1. Italy Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Nasopharyngeal Carcinoma Treatment Market

• 20.1. Spain Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Nasopharyngeal Carcinoma Treatment Market

• 21.1. Eastern Europe Nasopharyngeal Carcinoma Treatment Market Overview
• 21.2. Eastern Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Nasopharyngeal Carcinoma Treatment Market

• 22.1. Russia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Nasopharyngeal Carcinoma Treatment Market

• 23.1. North America Nasopharyngeal Carcinoma Treatment Market Overview
• 23.2. North America Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Nasopharyngeal Carcinoma Treatment Market

• 24.1. USA Nasopharyngeal Carcinoma Treatment Market Overview
• 24.2. USA Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Nasopharyngeal Carcinoma Treatment Market

• 25.1. Canada Nasopharyngeal Carcinoma Treatment Market Overview
• 25.2. Canada Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Nasopharyngeal Carcinoma Treatment Market

• 26.1. South America Nasopharyngeal Carcinoma Treatment Market Overview
• 26.2. South America Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Nasopharyngeal Carcinoma Treatment Market

• 27.1. Brazil Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Nasopharyngeal Carcinoma Treatment Market

• 28.1. Middle East Nasopharyngeal Carcinoma Treatment Market Overview
• 28.2. Middle East Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Nasopharyngeal Carcinoma Treatment Market

• 29.1. Africa Nasopharyngeal Carcinoma Treatment Market Overview
• 29.2. Africa Nasopharyngeal Carcinoma Treatment Market, Segmentation By Types, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Nasopharyngeal Carcinoma Treatment Market, Segmentation By Drug, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Nasopharyngeal Carcinoma Treatment Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Nasopharyngeal Carcinoma Treatment Market Competitive Landscape And Company Profiles

• 30.1. Nasopharyngeal Carcinoma Treatment Market Competitive Landscape
• 30.2. Nasopharyngeal Carcinoma Treatment Market Company Profiles
  • 30.2.1. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Nasopharyngeal Carcinoma Treatment Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. Eli Lilly and Company
• 31.3. Amgen Inc.
• 31.4. C.H. Boehringer Sohn AG & Co. KG.
• 31.5. Regeneron Pharmaceuticals Inc.
• 31.6. Astellas Pharma Inc.
• 31.7. Eisai Co. Ltd.
• 31.8. Incyte Corporation
• 31.9. Ipsen S.A.
• 31.10. Dr. Reddys Laboratories Ltd.
• 31.11. Hikma Pharmaceuticals plc
• 31.12. Exelixis Inc.
• 31.13. BeiGene Ltd
• 31.14. Taiho Pharmaceutical Co. Ltd.
• 31.15. Simcere Pharmaceutical Group

32. Global Nasopharyngeal Carcinoma Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Nasopharyngeal Carcinoma Treatment Market

34. Recent Developments In The Nasopharyngeal Carcinoma Treatment Market

35. Nasopharyngeal Carcinoma Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Nasopharyngeal Carcinoma Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Nasopharyngeal Carcinoma Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Nasopharyngeal Carcinoma Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer